MANNKIND CORP Deferred Revenue
MANNKIND CORP (MNKD) had Deferred Revenue of $3.04 million as of 2017-12-31, per its 10-K filed 2019-02-26.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2019-02-26
- 2017-12-31: Deferred Revenue, Current $3.04M.
- 2017-09-30: Deferred Revenue, Current $3.02M.
- 2017-06-30: Deferred Revenue, Current $2.59M.
- 2017-03-31: Deferred Revenue, Current $1.84M.
| Period end | Deferred Revenue, Current | Deferred Revenue, Current as first filed |
|---|---|---|
| 2017-12-31 | $3.04M 10-K · filed 2019-02-26 | |
| 2017-09-30 | $3.02M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $2.59M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $1.84M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $3.42M 10-K · filed 2018-02-27 | |
| 2016-09-30 | $2.01M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $135.23M 10-Q/A · filed 2016-08-10 | $144.43M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $134.94M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $140.23M 10-Q/A · filed 2016-08-10 | |
| 2015-09-30 | $157.15M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $171.85M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $185.06M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $196.97M 10-K · filed 2016-03-15 | $197.40M 10-K · filed 2015-03-02 |
| 2014-09-30 | $150.00M 10-Q · filed 2014-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |